RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
December 30, 2015
RegMed’s close: with little volume, it's easy to move the sector either way
December 30, 2015
Regenxbio (RGNX) FDA has granted Rare Pediatric Disease designation
December 29, 2015
RegMed’s close: blurred performance
December 22, 2015
RegMed’s close: pressured to the downside
December 18, 2015
RegMed’s close: volume was up and volatility was relatively moderate
December 16, 2015
RegMed’s close: Stocks surge but, caution should be your middle name
December 14, 2015
RegMed’s close: the sector opened strong to implode by the first half-hour
December 10, 2015
RegMed’s close: why close the barn door when the appreciation is leaving on its own
December 9, 2015
RegMed’s close: mired in disappointment
November 27, 2015
RegMed’s close: what’s more dangerous than the lesson of price swing bubbles?
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.